Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Adaptive Biotechnologies

Adaptive Biotechnologies

A company focused on profiling T-cell and B-cell receptors using sequencing and bioinformatics to create a population level immunomics database

Adaptive Biotechnologies develops clinical products for detection and treatment of disease in partnership with Microsoft using an immune medicine platform and machine learning capabilities. The company aims to map population-wide adaptive immune responses in an immunomics database that can enable earlier detection of disease through immune response signatures. Immune response signatures can also be used to design therapeutics.

ImmunoSeq technology is used to sequence the genetic code of T cell receptors and B cell receptors and map them to the antigens they bind to using Mira technology. This shows which diseases a patient’s immune system has been exposed to or is actively fighting. The data linking T cell receptors and antigens is analysed with Microsoft machine learning tools to create a map of antigens and receptors, an immunomics database. Applications include diagnostic testing and therapeutics. Adaptive biotechnologies has a system called PairSeq for reconstructing both chains of the Y shaped receptor for therapeutic purposes. TruTCR is an analytical process to determine optimal candidates for TCR-mediated T-cell therapies.

Adaptive Biotechnologies is applying their technology in partnership with Microsoft to decode the immune response to COVID-19 (SARS-CoV-2 virus) for the purpose of accelerating the development of detection methods and vaccine discovery. Data will be freely available around the world to researchers, public health officials or organizations. Adaptive believes their population level immune response data can be used to help diagnose the virus asymptomatic infected people and improve triaging of newly diagnosed patients and also help find immune response signatures that are relevant to the development of treatments and preventions for COVID-19.

Timeline

May 7, 2015
Adaptive Biotechnologies raises a $805,000,000 series F round from Matrix Capital Management, Rock Springs Capital, Senator Investor Group and Tiger Management Corp..
January 7, 2015
Adaptive Biotechnologies raises a $94,000,000 series E round.
April 15, 2014
Adaptive Biotechnologies raises a $100,000,000 series D round from Viking Global Investors.
April 7, 2014
Adaptive Biotechnologies raises a $5,000,000 series C round from Viking Global Investors.
September 13, 2013
Adaptive Biotechnologies raises a $2,500,000 grant.
June 10, 2011
Adaptive Biotechnologies raises a $5,800,000 series B round.
March 24, 2010
Adaptive Biotechnologies raises a $4,600,000 series A round.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Heather Landi
March 11, 2021
FierceHealthcare
Adaptive Biotechnologies launched a new diagnostic test for COVID-19 that uses machine learning technology from Microsoft to detect prior coronavirus infections.
International New York Times
November 11, 2020
Deccan Herald
A new type of test can detect a person's immune response to the coronavirus better than a widely used antibody test, according to research released on Tuesday. The test, if authorized by the Food and Drug Administration, would be the first commercial product to detect the response of a T cell -- a type of immune cell -- to the virus. Antibodies have dominated the conversation on
BioSpace
November 10, 2020
BioSpace
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with GlaxoSmithKline plc (GSK) to use its clonoSEQ ® Assay to assess minimal residual disease (MRD) in GSK's portfolio of hematology products. "We are thrilled to collaborate with GSK to implement our leadi
June 11, 2020
BioSpace
Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus - read this article along with other careers information, tips and advice on BioSpace
Chelsea Weidman Burke, M.S.
May 26, 2020
BioSpace
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.

References

Golden logo
By using this site, you agree to our Terms & Conditions.